



GEORGIA DEPARTMENT
OF COMMUNITY HEALTH

Georgia Department of Community Health

DRUG UTILIZATION REVIEW BOARD MEETING

Department of Community Health
2 Peachtree Street – 5th Floor Board Room
Atlanta, Georgia 30303

August 7, 2018

This page intentionally left blank



DRUG UTILIZATION REVIEW BOARD MEETING

AGENDA

2 Peachtree Street - 5th Floor DCH Board Room

Atlanta, Georgia 30303

Tuesday, August 7, 2018

10:00 a.m. to 2:00 p.m.

CALL TO ORDER

Burton L. Lesnick, M.D., FAAP, Chair

MINUTES FROM PREVIOUS MEETING

Chair

EXTERNAL COMMENTS SESSION

Chair

CLINICAL REVIEWS

Afzal Mistry, PharmD, NorthStar

Chad Nicholson, PharmD, NorthStar

Emily Baker, PharmD, BCPS, NorthStar

➤ New Drugs

- Baxdela
- Biktarvy
- Ozempic
- Parsabiv
- Steglatro
- Symdeko

ADJOURNMENT OF OPEN SESSION

Chair

EXECUTIVE SESSION

*Nina Bandali, PharmD, Pharmacist Account
Manager, Magellan Rx Management*

RECONVENING OF OPEN SESSION

Chair

BOARD'S RECOMMENDATIONS AND VOTES

Chair

FUTURE AGENDA ITEMS

Chair

ADJOURNMENT OF MEETING

Chair

This page intentionally left blank

**Department of Community Health
Drug Utilization Review Board (DURB)
MINUTES
Tuesday, May 1, 2018**

MEMBERS PRESENT

Burton L. Lesnick, M.D., FAAP, Chair
M. Celeste Fowler, Pharm.D., Vice-Chair
Mia Avery, Pharm.D.
Doug Collins, M.D.
Gurinder J.S. Doad, M.D.
Rod M. Duraski, M.D., FACP, MBA
Deborah Fincher, M.S., R.Ph
Glenda Wrenn Gordon, M.D.
Yolanda P. Graham, M.D.
Robyn Lorys, Pharm.D.
J. Russell May, Pharm.D.
Osgood (Drew) A. Miller, R.Ph.
Brent L. Rollins, R.Ph., Ph.D.
Danny A. Toth, R.Ph.

MEMBERS ABSENT

Staff

Peter D'Alba, R.Ph., Pharmacy Director, Pharmacy Services
Gilletta Gray, R.Ph., Clinical Manager, Pharmacy Services
Lori Garner, MHS, MBA, R.Ph., Pharmacist, Pharmacy Services
Maria Lucas, Pharmacy Program Specialist, Pharmacy Services
Rebecca Morrison, Pharmacy Program Specialist, Pharmacy Services
Karla Forbes, Pharm.D., Program Integrity

NorthStar HealthCare Consulting

Afzal "Fez" Mistry, Pharm.D., Clinical Programs Director
Chad Nicholson, Pharm.D., Clinical Pharmacist

OptumRx

Mark Hall, MBA, PMP, Assoc. Director, Government Markets, Relations & Reform
Talmahjia "Tami" Sweat, Pharm.D., Director, Clinical Management

Magellan Rx Management

Chris Andrews, Pharm.D., VP, Pharmacy Pricing and Value Based Purchasing
Nina Bandali, Pharm.D., Pharmacist Account Manager

Care Management Organizations

Turkesia Robertson-Jones, Pharm.D., CareSource

**Department of Community Health
Drug Utilization Review Board (DURB)
MINUTES**

Tuesday, May 1, 2018

Call to Order

The Drug Utilization Review Board (DURB/DUR Board/Board) held its second meeting for the calendar year on May 1, 2018. The Chair, Burton L. Lesnick, M.D., FAAP, called the meeting to order at 10:00am.

Comments from the Department

There were no comments from the Department.

Minutes from the Previous Meeting

Chair Lesnick asked for corrections or changes to the minutes from the February 6, 2018 meeting. A motion was made (Yolanda P Graham, M.D.), seconded (Robyn Lorys, Pharm.D.), and carried to approve the minutes as written.

External Comments Session

External comments were presented to the Board from the following:

- Robert Sidonio, Jr., M.D. (Children's Healthcare of Atlanta) – spoke about Hemlibra, administration, cost savings, reduced bleeds, ITI therapy and safety concerns (deaths).
- Christine Kempton, M.D. (Emory University) – spoke about adult treatment on Hemlibra.
- Neil Campbell, Executive Director, (Georgia Council of Substance Abuse) – spoke about opioid crisis and lack of access to appropriate care.
- A letter from Sharon Cooper, Georgia State Representative (Chairman of House Health and Human Services Committee) – requested inclusion of all single tablet regimens on formulary.
- A letter from Cathalene Teahan, RN, MSN (GA AIDS Coalition) – requested inclusion of all single tablet regimens on formulary and open access.

Disclosure forms were completed by Dr. Robert Sidonio, Jr., Dr. Christine Kempton, Ms. Neil Campbell, Representative Sharon Cooper, and Ms. Cathalene Teahan and were reviewed by the Department.

Opioid Presentation

Afzal "Fez" Mistry, Pharm.D., provided background information on the impact of the Opioid epidemic on Medicaid beneficiaries, highlighted strategies for preventing Opioid-related harm (with a focus on methadone and concurrent use of Opioids and benzodiazepines), and solicited feedback/recommendations from DURB members. The Board discussed the information, provided comments, and raised questions on the following:

- Risk of overdose in using methadone for pain vs. substance abuse – CMS guidance directed for use in pain
- Opioid deaths – related to prescription use
- Important to view subject comprehensively
- Methadone has its niche in terms of treatment; safety issues due to people
- Taking methadone off the PDL may result in paperwork/appeals
- PDMP – may be a vehicle to use
- Seen more quantity and amount restrictions in place by insurers
- Consider making physicians aware of refill intervals
- More physicians not writing for opioids
- Not many methadone clinics outside Atlanta area

Department of Community Health
Drug Utilization Review Board (DURB)
MINUTES

Tuesday, May 1, 2018

- Look at claims history – provider ID, prescription surveillance, early refills, increase access to other MATs, use of other narcotics
- Access medical claims data – look at individuals presenting in ER/inpatient with drug overdose as it relates to our population and areas that don't have methadone clinics
- Implement refill threshold changes
- Georgia one of few states with methadone on the PDL
- Restrict to specialists
- Few treatment center options available
- Behavioral therapy required for MAT
- Need an action plan in place for the individuals that need the medication; look at financial impact

New Drug Reviews

Clinical information for the following new drugs, in the market six months or more, was presented for discussion and recommendations. The complete detailed drug summary is in the New Drugs for Review section of the DUR Board binder.

Therapeutic Class	Drugs	Presenter
Hemophilia Treatment	<i>Hemlibra</i>	Afzal “Fez” Mistry, Pharm.D.
Hemophilia Treatment	<i>Rebinyn</i>	Afzal “Fez” Mistry, Pharm.D.
Gastrointestinal Motility, Chronic	<i>Symproic</i>	Afzal “Fez” Mistry, Pharm.D.

The Board discussed the drug information, provided comments, and raised questions on the following:

Hemlibra – validity of numbers in pharmacoeconomic analysis; look at financial impact to drug class; safety black box warning with Feiba, some physicians may be more comfortable with Novoseven.

Rebinyn – depends on type of bleed whether treatment is outpatient vs. inpatient.

DCH Decisions

DCH Decisions from the February 2018 DUR Board meeting were provided in the DCH Decision section of the DUR Board binder.

Upcoming Meetings

The following upcoming meetings were published in the DURB binder:

- Drug Utilization Review Board
2 Peachtree Street NW
5th Floor Board Room
Atlanta, Georgia 30303

Tuesday, August 7, 2018

Tuesday, November 6, 2018

Department of Community Health
Drug Utilization Review Board (DURB)
MINUTES

Tuesday, May 1, 2018

Disclosure Forms

Disclosure forms were received and reviewed by the Department for completeness for all Board members attending the meeting.

Adjournment of Open Session

The DUR Board voted to close the open meeting pursuant to the Open Meeting Act of Georgia Section 50-14-1 – 50-14-6 and pursuant to Federal Law Section 1396R-8B3D. The individuals recorded in attendance with the Board members were from the Department of Community Health, Magellan Rx Management, and NorthStar HealthCare Consulting. CMO representative, Turkesia Robertson-Jones, Pharm.D. (CareSource), attended the closed session with Board members. A motion was made by Robyn Lorys, Pharm.D., and seconded by Danny Toth, R.Ph., to adjourn the open session and approve the closed session. There was a unanimous vote approving the closed session. The Chairman, Burton L. Lesnick, M.D., FAAP, adjourned the open session at approximately 11:40am, at which time members took a break then reconvened for the executive (closed) session.

Executive Session

The Executive Session was held from 12:05am to 1:45pm.

Reconvening of Open Session

The DUR Board reconvened for the open session at 1:51pm.

External Comments (continued)

External comments were presented to the Board from the following:

- Daniel Driffin, Co-Founder of THRIVESS (Transforming HIV Resentment into Victories Everlasting Support Services) – spoke about open access to single tablet regimens and other antiretroviral therapies.

A disclosure form was completed by Mr. Daniel Driffin and was reviewed by the Department.

Board's Recommendations to the Department

After all clinical and financial evaluations and discussions, the DUR Board voted and presented the Department with the following recommendations for changes to the Preferred Drug List (PDL) as noted in Attachment A. All motions and votes are noted in Attachment B.

Future Agenda Items

There were no future agenda items noted.

Conclusion

At the conclusion of the reconvened open session and no other business for discussion, there was a unanimous decision to adjourn the meeting. Chair Lesnick adjourned the meeting at 2:13pm.

THESE MINUTES ARE HEREBY APPROVED AND ADOPTED, THIS THE _____
DAY OF _____, 2018.

Burton L. Lesnick, M.D., FAAP, Chair

Drug Utilization Review Board

Motions - Votes

May 1, 2018

New Drugs Review		Drug (* New)	PDL Status	Motion - Recommendations	Additional Comments	
Hemophilia Treatment		FEIBA (Intravenous) Injection	P	NPPA		
		*Hemlibra (Subcutaneous) Injection	NA	P/PA		
		Novoeight (Intravenous) Injection	NP/PA	P		
		NovoSeven RT (Intravenous) Injection	P	NPPA		
		Nuwiq (Intravenous) Injection	NP/PA	P		
		*Rebinyn (Intravenous) Injection	NA	NPPA		
Board Members - Present <small>(Strike out, when absent)</small>		Motion Maker (v)	Seconded By (v)	VOTES		
				YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.			✓		
2	Collins, Douglas, M.D.	✓		✓		
3	Doad, Gurinder J.S., M.D.-			✓		
4	Duraski, Rod, M.D.			✓		
5	Fincher, Deborah W., M.S., R.Ph.			✓		
6	Fowler, M. Celeste, Pharm.D. - Vice			✓		
7	Gordon, Glenda Wrenn		✓	✓		
8	Graham, Yolanda, M.D.			✓		
9	Lesnick, Burton, M.D. - Chair			✓		
10	Lorys, Robyn Pharm.D.			✓		
11	May, J. Russell (Rusty)			✓		
12	Miller, Osgood (Drew) A. R.Ph.			✓		
13	Rollins, Brent L., R.Ph., Ph.D.			✓		
14	Toth, Danny, R.Ph.			✓		
TOTAL				14	0	0

Drug Utilization Review Board

Motions - Votes

May 1, 2018

New Drug Review		Drug (* New)	PDL Status	Motion - Recommendations	Additional Comments	
Gastrointestinal Motility, Chronic		Amitiza (Oral) Capsule	NP/PA	P/PA		
		*Symproic (Oral) Tablet	NA	NP/PA		
Board Members - Present <small>(Strike out, when absent)</small>		Motion Maker (v)	Seconded By (v)	VOTES		
				YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.			✓		
2	Collins, Douglas, M.D.			✓		
3	Doad, Gurinder J.S., M.D.-			✓		
4	Duraski, Rod, M.D.	✓		✓		
5	Fincher, Deborah W., M.S., R.Ph.			✓		
6	Fowler, M. Celeste, Pharm.D. - Vice			✓		
7	Gordon, Glenda Wrenn			✓		
8	Graham, Yolanda, M.D.			✓		
9	Lesnick, Burton, M.D. - Chair			✓		
10	Lorys, Robyn Pharm.D.		✓	✓		
11	May, J. Russell (Rusty)			✓		
12	Miller, Osgood (Drew) A. R.Ph.			✓		
13	Rollins, Brent L., R.Ph., Ph.D.			✓		
14	Toth, Danny, R.Ph.			✓		
			TOTAL	14	0	0

Drug Utilization Review Board

Motions - Votes

May 1, 2018

Supplemental Rebate Review		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Analgesics, Narcotics Long		Kadian (Oral) Capsule	P	NP/PA		
		Methadone (Oral) Tablet/Solution	P	NP		
Board Members - Present <small>(Strike out, when absent)</small>		Motion Maker (v)	Seconded By (v)	VOTES		
				YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.			✓		
2	Collins, Douglas, M.D.			✓		
3	Doad, Gurinder J.S., M.D.-			✓		
4	Duraski, Rod, M.D.			✓		
5	Fincher, Deborah W., M.S., R.Ph.			✓		
6	Fowler, M. Celeste, Pharm.D. - Vice			✓		
7	Gordon, Glenda Wrenn			✓		
8	Graham, Yolanda, M.D.			✓		
9	Lesnick, Burton, M.D. - Chair			✓		
10	Lorys, Robyn Pharm.D.			✓		
11	May, J. Russell (Rusty)			✓		
12	Miller, Osgood (Drew) A. R.Ph.		✓	✓		
13	Rollins, Brent L., R.Ph., Ph.D.	✓		✓		
14	Toth, Danny, R.Ph.			✓		
			TOTAL	14	0	0

Drug Utilization Review Board

Motions - Votes

May 1, 2018

Supplemental Rebate Review		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Angiotensin Modulator Combinations		Azor (Oral) Tablet	P/PA	NP/PA		
		Trandolapril/Verapamil (Oral) Tablet	P	NP/PA		
		Tribenzor (Oral) Tablet	P/PA	NP/PA		
Board Members - Present		Motion Maker (v)	Seconded By (v)	VOTES		
(Strike out, when absent)				YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.			✓		
2	Collins, Douglas, M.D.			✓		
3	Doad, Gurinder J.S., M.D.-			✓		
4	Duraski, Rod, M.D.			✓		
5	Fincher, Deborah W., M.S., R.Ph.			✓		
6	Fowler, M. Celeste, Pharm.D. - Vice			✓		
7	Gordon, Glenda Wrenn			✓		
8	Graham, Yolanda, M.D.			✓		
9	Lesnick, Burton, M.D. - Chair			✓		
10	Lorys, Robyn Pharm.D.	✓		✓		
11	May, J. Russell (Rusty)			✓		
12	Miller, Osgood (Drew) A. R.Ph.			✓		
13	Rollins, Brent L., R.Ph., Ph.D.			✓		
14	Toth, Danny, R.Ph.		✓	✓		
TOTAL				14	0	0

Drug Utilization Review Board

Motions - Votes

May 1, 2018

Supplemental Rebate Review		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Antianginal & Anti-Ischemic		Ranexa (Oral) Tablet	NP/PA	P/PA		
Board Members - Present		Motion Maker (v)	Seconded By (v)	VOTES		
(Strike out, when absent)				YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.			✓		
2	Collins, Douglas, M.D.			✓		
3	Doad, Gurinder J.S., M.D.-			✓		
4	Duraski, Rod, M.D.			✓		
5	Fincher, Deborah W., M.S., R.Ph.			✓		
6	Fowler, M. Celeste, Pharm.D. - Vice			✓		
7	Gordon, Glenda Wrenn			✓		
8	Graham, Yolanda, M.D.			✓		
9	Lesnick, Burton, M.D. - Chair			✓		
10	Lorys, Robyn Pharm.D.			✓		
11	May, J. Russell (Rusty)		✓	✓		
12	Miller, Osgood (Drew) A. R.Ph.	✓		✓		
13	Rollins, Brent L., R.Ph., Ph.D.			✓		
14	Toth, Danny, R.Ph.			✓		
			TOTAL	14	0	0

Drug Utilization Review Board

Motions - Votes

May 1, 2018

Supplemental Rebate Review		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Antibiotics, Vaginal		Clindesse (Vaginal) Cream	NP/PA	P		
Board Members - Present		Motion Maker (v)	Seconded By (v)	VOTES		
(Strike out, when absent)				YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.			✓		
2	Collins, Douglas, M.D.			✓		
3	Doad, Gurinder J.S., M.D.-			✓		
4	Duraski, Rod, M.D.			✓		
5	Fincher, Deborah W., M.S., R.Ph.	✓		✓		
6	Fowler, M. Celeste, Pharm.D. - Vice			✓		
7	Gordon, Glenda Wrenn			✓		
8	Graham, Yolanda, M.D.			✓		
9	Lesnick, Burton, M.D. - Chair			✓		
10	Lorys, Robyn Pharm.D.		✓	✓		
11	May, J. Russell (Rusty)			✓		
12	Miller, Osgood (Drew) A. R.Ph.			✓		
13	Rollins, Brent L., R.Ph., Ph.D.			✓		
14	Toth, Danny, R.Ph.			✓		
			TOTAL	14	0	0

Drug Utilization Review Board

Motions - Votes

May 1, 2018

Supplemental Rebate Review		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Anticoagulants		Enoxaparin (Subcutaneous) Vial	P	NP/PA		
		Enoxaparin (Subcutaneous) Syringe [only Non-Authorized Generic	P	NP/PA		
		Fragmin (Subcutaneous) Injection	P	NP/PA		
Board Members - Present	Motion Maker (v)	Seconded By (v)	VOTES			
(Strike out, when absent)			YES (v)	NO (v)	ABSTAIN (v)	
1	Avery, Mia, Pharm.D.			✓		
2	Collins, Douglas, M.D.			✓		
3	Doad, Gurinder J.S., M.D.-	✓		✓		
4	Duraski, Rod, M.D.			✓		
5	Fincher, Deborah W., M.S., R.Ph.			✓		
6	Fowler, M. Celeste, Pharm.D. - Vice			✓		
7	Gordon, Glenda Wrenn			✓		
8	Graham, Yolanda, M.D.			✓		
9	Lesnick, Burton, M.D. - Chair			✓		
10	Lorys, Robyn Pharm.D.			✓		
11	May, J. Russell (Rusty)			✓		
12	Miller, Osgood (Drew) A. R.Ph.		✓	✓		
13	Rollins, Brent L., R.Ph., Ph.D.			✓		
14	Toth, Danny, R.Ph.			✓		
			TOTAL	14	0	0

Drug Utilization Review Board

Motions - Votes

May 1, 2018

Supplemental Rebate Review		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Antiemetic/Antivertigo Agents		Compro (Rectal) Suppository	P	NP		
		Emend (Oral) Capsule	NP	P		
		Promethazine 50 mg (Rectal) Suppository	P	NP		
		Trimethobenzamide (Oral) Capsule	P	NP		
Board Members - Present <small>(Strike out, when absent)</small>		Motion Maker (v)	Seconded By (v)	VOTES		
				YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.			✓		
2	Collins, Douglas, M.D.			✓		
3	Doad, Gurinder J.S., M.D.-			✓		
4	Duraski, Rod, M.D.			✓		
5	Fincher, Deborah W., M.S., R.Ph.			✓		
6	Fowler, M. Celeste, Pharm.D. - Vice			✓		
7	Gordon, Glenda Wrenn			✓		
8	Graham, Yolanda, M.D.			✓		
9	Lesnick, Burton, M.D. - Chair			✓		
10	Lorys, Robyn Pharm.D.			✓		
11	May, J. Russell (Rusty)	✓		✓		
12	Miller, Osgood (Drew) A. R.Ph.		✓	✓		
13	Rollins, Brent L., R.Ph., Ph.D.			✓		
14	Toth, Danny, R.Ph.			✓		
			TOTAL	14	0	0

Drug Utilization Review Board

Motions - Votes

May 1, 2018

Supplemental Rebate Review		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Antimigraine Agents, Triptans		Naratriptan (Oral) Tablet	P	NP		
		Sumatriptan (Subcutaneous) Vial, Syringes, Kit	P	NP		
Board Members - Present <small>(Strike out, when absent)</small>		Motion Maker (v)	Seconded By (v)	VOTES		
				YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.	✓		✓		
2	Collins, Douglas, M.D.			✓		
3	Doad, Gurinder J.S., M.D.-			✓		
4	Duraski, Rod, M.D.			✓		
5	Fincher, Deborah W., M.S., R.Ph.			✓		
6	Fowler, M. Celeste, Pharm.D. - Vice		✓	✓		
7	Gordon, Glenda Wrenn			✓		
8	Graham, Yolanda, M.D.			✓		
9	Lesnick, Burton, M.D. - Chair			✓		
10	Lorys, Robyn Pharm.D.			✓		
11	May, J. Russell (Rusty)			✓		
12	Miller, Osgood (Drew) A. R.Ph.			✓		
13	Rollins, Brent L., R.Ph., Ph.D.			✓		
14	Toth, Danny, R.Ph.			✓		
			TOTAL	14	0	0

Drug Utilization Review Board

Motions - Votes

May 1, 2018

Supplemental Rebate Review		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Bladder Relaxant Preparations		Flavoxate (Oral) Tablet	P	NP		
Board Members - Present		Motion Maker (v)	Seconded By (v)	VOTES		
(Strike out, when absent)				YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.			✓		
2	Collins, Douglas, M.D.			✓		
3	Doad, Gurinder J.S., M.D.-			✓		
4	Duraski, Rod, M.D.			✓		
5	Fincher, Deborah W., M.S., R.Ph.			✓		
6	Fowler, M. Celeste, Pharm.D. - Vice			✓		
7	Gordon, Glenda Wrenn			✓		
8	Graham, Yolanda, M.D.			✓		
9	Lesnick, Burton, M.D. - Chair			✓		
10	Lorys, Robyn Pharm.D.			✓		
11	May, J. Russell (Rusty)			✓		
12	Miller, Osgood (Drew) A. R.Ph.	✓		✓		
13	Rollins, Brent L., R.Ph., Ph.D.			✓		
14	Toth, Danny, R.Ph.		✓	✓		
			TOTAL	14	0	0

Drug Utilization Review Board

Motions - Votes

May 1, 2018

Supplemental Rebate Review		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Botulinum Toxins		Myobloc (Intramuscular) Injection	P	NP		
		Xeomin (Intramuscular) Injection	P	NP		
Board Members - Present	Motion Maker (v)	Seconded By (v)	VOTES			
(Strike out, when absent)			YES (v)	NO (v)	ABSTAIN (v)	
1	Avery, Mia, Pharm.D.			√		
2	Collins, Douglas, M.D.					
3	Doad, Gurinder J.S., M.D.-			√		
4	Duraski, Rod, M.D.			√		
5	Fincher, Deborah W., M.S., R.Ph.			√		
6	Fowler, M. Celeste, Pharm.D. - Vice			√		
7	Gordon, Glenda Wrenn		√	√		
8	Graham, Yolanda, M.D.			√		
9	Lesnick, Burton, M.D. - Chair			√		
10	Lorys, Robyn Pharm.D.	√		√		
11	May, J. Russell (Rusty)			√		
12	Miller, Osgood (Drew) A. R.Ph.			√		
13	Rollins, Brent L., R.Ph., Ph.D.			√		
14	Toth, Danny, R.Ph.			√		
			TOTAL	13	0	0

Drug Utilization Review Board

Motions - Votes

May 1, 2018

Supplemental Rebate Review		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Cephalosporins and Related Antibiotics		Amoxicillin/Clavulanate (Oral) Chewable Tablet	P	NP/PA		
		Augmentin 125 mg/5 mL (Oral) Suspension	P	NP/PA		
		Cefaclor (Oral) Extended-Release Tablet	P	NP/PA		
		Cefadroxil (Oral) Tablet	P	NP/PA		
		Cefpodoxime (Oral) Suspension	P	NP/PA		
		Cefpodoxime (Oral) Tablet	P	NP/PA		
Board Members - Present	Motion Maker (v)	Seconded By (v)	VOTES			
(Strike out, when absent)			YES (v)	NO (v)	ABSTAIN (v)	
1	Avery, Mia, Pharm.D.		✓	✓		
2	Collins, Douglas, M.D.			✓		
3	Doad, Gurinder J.S., M.D.-	✓		✓		
4	Duraski, Rod, M.D.			✓		
5	Fincher, Deborah W., M.S., R.Ph.			✓		
6	Fowler, M. Celeste, Pharm.D. - Vice			✓		
7	Gordon, Glenda Wrenn			✓		
8	Graham, Yolanda, M.D.			✓		
9	Lesnick, Burton, M.D. - Chair			✓		
10	Lorys, Robyn Pharm.D.			✓		
11	May, J. Russell (Rusty)			✓		
12	Miller, Osgood (Drew) A. R.Ph.			✓		
13	Rollins, Brent L., R.Ph., Ph.D.			✓		
14	Toth, Danny, R.Ph.			✓		
TOTAL				14	0	0

Drug Utilization Review Board

Motions - Votes

May 1, 2018

Supplemental Rebate Review		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Cytokine and CAM Antagonists		Xeljanz (Oral) Tablet	NP/PA	P/PA		
		Xeljanz (Oral) Extended-Release Tablet	NP/PA	P/PA		
Board Members - Present <small>(Strike out, when absent)</small>		Motion Maker (v)	Seconded By (v)	VOTES		
				YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.			✓		
2	Collins, Douglas, M.D.			✓		
3	Doad, Gurinder J.S., M.D.-			✓		
4	Duraski, Rod, M.D.			✓		
5	Fincher, Deborah W., M.S., R.Ph.			✓		
6	Fowler, M. Celeste, Pharm.D. - Vice			✓		
7	Gordon, Glenda Wrenn			✓		
8	Graham, Yolanda, M.D.			✓		
9	Lesnick, Burton, M.D. - Chair			✓		
10	Lorys, Robyn Pharm.D.			✓		
11	May, J. Russell (Rusty)		✓	✓		
12	Miller, Osgood (Drew) A. R.Ph.	✓		✓		
13	Rollins, Brent L., R.Ph., Ph.D.			✓		
14	Toth, Danny, R.Ph.			✓		
			TOTAL	14	0	

Drug Utilization Review Board

Motions - Votes

May 1, 2018

Supplemental Rebate Review		Drug	PDL Status	Motion - Recommendations	Additional Comments	
HAE Treatments		Haegarda (Subcutaneous) Injection	P	NP/PA		
		Ruconest (Intravenous) Injection	P	NP/PA		
Board Members - Present <small>(Strike out, when absent)</small>		Motion Maker (v)	Seconded By (v)	VOTES		
				YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.			✓		
2	Collins, Douglas, M.D.			✓		
3	Doad, Gurinder J.S., M.D.-	✓		✓		
4	Duraski, Rod, M.D.			✓		
5	Fincher, Deborah W., M.S., R.Ph.			✓		
6	Fowler, M. Celeste, Pharm.D. - Vice			✓		
7	Gordon, Glenda Wrenn			✓		
8	Graham, Yolanda, M.D.			✓		
9	Lesnick, Burton, M.D. - Chair			✓		
10	Lorys, Robyn Pharm.D.			✓		
11	May, J. Russell (Rusty)			✓		
12	Miller, Osgood (Drew) A. R.Ph.		✓	✓		
13	Rollins, Brent L., R.Ph., Ph.D.			✓		
14	Toth, Danny, R.Ph.			✓		
			TOTAL	14	0	

Drug Utilization Review Board

Motions - Votes

May 1, 2018

Supplemental Rebate Review		Drug	PDL Status	Motion - Recommendations	Additional Comments	
HIV/AIDS		Abacavir/Lamivudine (Oral) Tablet	NP/PA	P		
		Lamivudine (Oral) Solution	NP/PA	P		
Board Members - Present	Motion Maker (v)	Seconded By (v)	VOTES			
(Strike out, when absent)			YES (v)	NO (v)	ABSTAIN (v)	
1	Avery, Mia, Pharm.D.			✓		
2	Collins, Douglas, M.D.			✓		
3	Doad, Gurinder J.S., M.D.-			✓		
4	Duraski, Rod, M.D.			✓		
5	Fincher, Deborah W., M.S., R.Ph.	✓		✓		
6	Fowler, M. Celeste, Pharm.D. - Vice			✓		
7	Gordon, Glenda Wrenn			✓		
8	Graham, Yolanda, M.D.			✓		
9	Lesnick, Burton, M.D. - Chair			✓		
10	Lorys, Robyn Pharm.D.			✓		
11	May, J. Russell (Rusty)			✓		
12	Miller, Osgood (Drew) A. R.Ph.		✓	✓		
13	Rollins, Brent L., R.Ph., Ph.D.			✓		
14	Toth, Danny, R.Ph.			✓		
			TOTAL	14	0	

Drug Utilization Review Board

Motions - Votes

May 1, 2018

Supplemental Rebate Review		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Hypoglycemics, Insulin and Related Agents		Humalog 200 units/mL (Subcutaneous) Pen	P/PA	NP		
		Humulin 70/30 (Subcutaneous) Vial	NP/PA	P		
		Humulin (Subcutaneous) Vial	NP/PA	P		
Board Members - Present					VOTES	
(Strike out, when absent)		Maker (v)	Seconded By (v)	YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.			✓		
2	Collins, Douglas, M.D.			✓		
3	Doad, Gurinder J.S., M.D.-			✓		
4	Duraski, Rod, M.D.			✓		
5	Fincher, Deborah W., M.S., R.Ph.			✓		
6	Fowler, M. Celeste, Pharm.D. - Vice			✓		
7	Gordon, Glenda Wrenn			✓		
8	Graham, Yolanda, M.D.			✓		
9	Lesnick, Burton, M.D. - Chair			✓		
10	Lorys, Robyn Pharm.D.	✓		✓		
11	May, J. Russell (Rusty)		✓	✓		
12	Miller, Osgood (Drew) A. R.Ph.			✓		
13	Rollins, Brent L., R.Ph., Ph.D.			✓		
14	Toth, Danny, R.Ph.			✓		
TOTAL				14	0	

Drug Utilization Review Board

Motions - Votes

May 1, 2018

Supplemental Rebate Review		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Laxatives & Cathartics		Gavilyte-H/Bisacodyl (Oral) Solution	P	NP		
Board Members - Present		Motion Maker (v)	Seconded By (v)	VOTES		
(Strike out, when absent)				YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.		✓	✓		
2	Collins, Douglas, M.D.			✓		
3	Doad, Gurinder J.S., M.D.-			✓		
4	Duraski, Rod, M.D.			✓		
5	Fincher, Deborah W., M.S., R.Ph.			✓		
6	Fowler, M. Celeste, Pharm.D. - Vice			✓		
7	Gordon, Glenda Wrenn			✓		
8	Graham, Yolanda, M.D.			✓		
9	Lesnick, Burton, M.D. - Chair			✓		
10	Lorys, Robyn Pharm.D.			✓		
11	May, J. Russell (Rusty)			✓		
12	Miller, Osgood (Drew) A. R.Ph.	✓		✓		
13	Rollins, Brent L., R.Ph., Ph.D.			✓		
14	Toth, Danny, R.Ph.			✓		
			TOTAL	14	0	0

Drug Utilization Review Board

Motions - Votes

May 1, 2018

Supplemental Rebate Review		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Lipotropics, Other		Fenofibrate (Oral) Tablet [generic Lofibra]	P	NP		
		Fenofibrate (Oral) Capsule [generic Lipofen]	P	NP		
		Fenofibrate (Oral) Micronized Capsule [generic Antara]	P	NP		
		Triglide (Oral) Tablet	P	NP		
Board Members - Present <small>(Strike out, when absent)</small>		Maker (v)	Seconded By (v)	VOTES		
				YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.			✓		
2	Collins, Douglas, M.D.			✓		
3	Doad, Gurinder J.S., M.D.-			✓		
4	Duraski, Rod, M.D.	✓		✓		
5	Fincher, Deborah W., M.S., R.Ph.			✓		
6	Fowler, M. Celeste, Pharm.D. - Vice			✓		
7	Gordon, Glenda Wrenn			✓		
8	Graham, Yolanda, M.D.			✓		
9	Lesnick, Burton, M.D. - Chair			✓		
10	Lorys, Robyn Pharm.D.			✓		
11	May, J. Russell (Rusty)			✓		
12	Miller, Osgood (Drew) A. R.Ph.			✓		
13	Rollins, Brent L., R.Ph., Ph.D.		✓	✓		
14	Toth, Danny, R.Ph.			✓		
TOTAL				14	0	

Drug Utilization Review Board

Motions - Votes

May 1, 2018

Supplemental Rebate Review		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Pancreatic Enzymes		Zenpep (Oral) Capsule	NP/PA	P		
Board Members - Present		Motion Maker (v)	Seconded By (v)	VOTES		
(Strike out, when absent)				YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.		✓	✓		
2	Collins, Douglas, M.D.			✓		
3	Doad, Gurinder J.S., M.D.-			✓		
4	Duraski, Rod, M.D.			✓		
5	Fincher, Deborah W., M.S., R.Ph.			✓		
6	Fowler, M. Celeste, Pharm.D. - Vice			✓		
7	Gordon, Glenda Wrenn			✓		
8	Graham, Yolanda, M.D.			✓		
9	Lesnick, Burton, M.D. - Chair			✓		
10	Lorys, Robyn Pharm.D.			✓		
11	May, J. Russell (Rusty)			✓		
12	Miller, Osgood (Drew) A. R.Ph.	✓		✓		
13	Rollins, Brent L., R.Ph., Ph.D.			✓		
14	Toth, Danny, R.Ph.			✓		
			TOTAL	14	0	0

Drug Utilization Review Board

Motions - Votes

May 1, 2018

Supplemental Rebate Review		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Phosphate Binders		Calcium Acetate (Oral) Tablet	P	NP/PA		
		Phoslyra (Oral) Solution	P	NP/PA		
Board Members - Present <small>(Strike out, when absent)</small>		Motion Maker (v)	Seconded By (v)	VOTES		
				YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.			✓		
2	Collins, Douglas, M.D.			✓		
3	Doad, Gurinder J.S., M.D.-			✓		
4	Duraski, Rod, M.D.	✓		✓		
5	Fincher, Deborah W., M.S., R.Ph.		✓	✓		
6	Fowler, M. Celeste, Pharm.D. - Vice			✓		
7	Gordon, Glenda Wrenn			✓		
8	Graham, Yolanda, M.D.			✓		
9	Lesnick, Burton, M.D. - Chair			✓		
10	Lorys, Robyn Pharm.D.			✓		
11	May, J. Russell (Rusty)			✓		
12	Miller, Osgood (Drew) A. R.Ph.			✓		
13	Rollins, Brent L., R.Ph., Ph.D.			✓		
14	Toth, Danny, R.Ph.			✓		
			TOTAL	14	0	

Drug Utilization Review Board

Motions - Votes

May 1, 2018

Supplemental Rebate Review		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Smoking Cessation		Chantix (Oral) Dose Pack	NP/PA	P		
		Chantix (Oral) Tablet	NP/PA	P		
Board Members - Present <small>(Strike out, when absent)</small>		Motion Maker (v)	Seconded By (v)	VOTES		
				YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.			✓		
2	Collins, Douglas, M.D.			✓		
3	Doad, Gurinder J.S., M.D.-			✓		
4	Duraski, Rod, M.D.			✓		
5	Fincher, Deborah W., M.S., R.Ph.			✓		
6	Fowler, M. Celeste, Pharm.D. - Vice			✓		
7	Gordon, Glenda Wrenn		✓	✓		
8	Graham, Yolanda, M.D.			✓		
9	Lesnick, Burton, M.D. - Chair			✓		
10	Lorys, Robyn Pharm.D.			✓		
11	May, J. Russell (Rusty)	✓		✓		
12	Miller, Osgood (Drew) A. R.Ph.			✓		
13	Rollins, Brent L., R.Ph., Ph.D.			✓		
14	Toth, Danny, R.Ph.			✓		
			TOTAL	14	0	

Drug Utilization Review Board

Motions - Votes

May 1, 2018

Supplemental Rebate Review		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Ulcerative Colitis Agents		Mesalamine (Rectal) Enema Suspension	P	NP/PA		
		Mesalamine (Rectal) Enema Suspension Kit	P	NP/PA		
Board Members - Present <small>(Strike out, when absent)</small>		Motion Maker (v)	Seconded By (v)	VOTES		
				YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.	✓		✓		
2	Collins, Douglas, M.D.			✓		
3	Doad, Gurinder J.S., M.D.-		✓	✓		
4	Duraski, Rod, M.D.			✓		
5	Fincher, Deborah W., M.S., R.Ph.			✓		
6	Fowler, M. Celeste, Pharm.D. - Vice			✓		
7	Gordon, Glenda Wrenn			✓		
8	Graham, Yolanda, M.D.			✓		
9	Lesnick, Burton, M.D. - Chair			✓		
10	Lorys, Robyn Pharm.D.			✓		
11	May, J. Russell (Rusty)			✓		
12	Miller, Osgood (Drew) A. R.Ph.			✓		
13	Rollins, Brent L., R.Ph., Ph.D.			✓		
14	Toth, Danny, R.Ph.			✓		
			TOTAL	14	0	

Drug Utilization Review Board

Motions - Votes

May 1, 2018

DURB RECOMMENDATIONS: No changes for the drugs in the following therapeutic classes

	Androgenic Agents	Antiparasitics, Topical	Hypoglycemics, Incretin Mimetics/Enhancers		Platelet Aggregation Inhibitors	
	Angiotensin Modulators	Growth Factors	Hypoglycemics, SGLT2		Prenatal Vitamins	
	Antibiotics, Inhaled	Growth Hormone	Multiple Sclerosis Agents			
	Antifibrinolytic Agents	Hepatitis C Agents	Opiate Dependence Treatments			
	Antifungals, Vaginal	Hyperparathyroid Agents	PAH Agents, Oral and Inhaled			
Board Members - Present <small>(Strike out, when absent)</small>		Motion Maker (v)	Seconded By (v)	VOTES		
				YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.		✓	✓		
2	Collins, Douglas, M.D.			✓		
3	Doad, Gurinder J.S., M.D.-			✓		
4	Duraski, Rod, M.D.			✓		
5	Fincher, Deborah W., M.S., R.Ph.			✓		
6	Fowler, M. Celeste, Pharm.D. - Vice	✓		✓		
7	Gordon, Glenda Wrenn			✓		
8	Graham, Yolanda, M.D.			✓		
9	Lesnick, Burton, M.D. - Chair			✓		
10	Lorys, Robyn Pharm.D.			✓		
11	May, J. Russell (Rusty)			✓		
12	Miller, Osgood (Drew) A. R.Ph.			✓		
13	Rollins, Brent L., R.Ph., Ph.D.			✓		
14	Toth, Danny, R.Ph.			✓		
			TOTAL	14	0	

This page intentionally left blank

Important Update

DCH Decision Document

Listed below are Preferred Drug List changes for the State of Georgia Fee-For-Service Medicaid and PeachCare for Kids Programs

Effective July 1, 2018 (see chart below)

DCH rebate vendor Magellan Medicaid Administration (MMA) has reviewed SFY2019 supplemental rebate offers with DCH and also reviewed specific drug categories at the May 2018 DURB meeting. The PDL/PADL decisions or PDL/PADL changes for new drugs or categories reviewed during the May DURB meeting are outlined below. **Those drugs highlighted in red indicate a change from current PDL status.** For a full listing of our PDL, go to www.dch.georgia.gov/pharmacy and select the “preferred product list” option.

PREFERRED AGENTS	NON-PREFERRED AGENTS
ONLY DRUGS with Supplemental Rebate Offer or reviewed during the May 2018 DURB meeting as either new to market or a change in PDL status are listed	
ANALGESICS, NARCOTICS LONG	
EMBEDA	ARYMO ER
	KADIAN
	METHADONE
	MORPHABOND ER
ANDROGENIC AGENTS	
ANDROGEL GEL PACKET, PUMP	
ANGIOTENSIN MODULATOR COMBINATIONS	
	AZOR
	EXFORGE
	EXFORGE HCT
	PRESTALIA
	TRANDOLAPRIL / VERAPAMIL (Authorized Generic)
	TRIBENZOR
ANGIOTENSIN MODULATORS	
ENTRESTO	
ANTIANGINAL & ANTI-ISCHEMIC	
RANEXA	
ANTIBIOTICS, INHALED	

PREFERRED AGENTS	NON-PREFERRED AGENTS
BETHKIS	TOBI PODHALER
KITABIS	
ANTIBIOTICS, VAGINAL	
CLINDESSE	
ANTICOAGULANTS	
ELIQUIS	ENOXAPARIN SODIUM VIAL (Authorized Generic & Non-Authorized Generic)
PRADAXA	ENOXAPARIN SYRINGE (Non-Authorized Generic)
XARELTO	FRAGMIN SYRINGE
	LOVENOX
ANTIEMETIC/ANTIVERTIGO AGENTS	
DICLEGIS	COMPRO
EMEND CAPSULE	PROMETHAZINE 50 MG RECTAL SUPPOSITORY
	TRIMETHOBENZAMIDE
ANTIFUNGALS, VAGINAL	
GYNAZOLE	
ANTIMIGRAINE AGENTS, TRIPTANS	
RELPAZ	NARATRIPTAN
	SUMATRIPTAN SYRINGE, KIT, VIAL
ANTIPARASITICS, TOPICAL	
NATROBA	
SKLICE	
BLADDER RELAXANT PREPARATIONS	
TOVIAZ	FLAVOXATE
	MYRBETRIQ
BOTULINUM TOXINS	
DYSPOZ	MYOBLOC
	XEOMIN
CEPHALOSPORINS AND RELATED ANTIBIOTICS	
SUPRAX CAPSULE	AMOXICILLIN/CLAV CHEW TABLET
	AUGMENTIN 125 SUSPENSION
	CEFACLOX TABLET ER
	CEFADROXIL TABLET
	CEFPODOXIME
CYTOKINE AND CAM ANTAGONISTS	
COSENTYX	KEVZARA
ENBREL	TALTZ
HUMIRA	
XELJANZ	

PREFERRED AGENTS	NON-PREFERRED AGENTS
XELJANZ XR	
GI MOTILITY, CHRONIC	
AMITIZA	LINZESS
	MOVANTIK
	SYMPROIC
GROWTH FACTORS	
EGRIFTA	
GROWTH HORMONE	
GENOTROPIN	ZOMACTON
NORDITROPIN	
NUTROPIN	
HAE TREATMENTS	
	HAEGARDA
	RUCONEST
HEMOPHILIA TREATMENT	
BENEFIX	FEIBA NF
HEMLIBRA	NOVOSEVEN RT
KOGENATE FS	REBINYN
NOVOEIGHT	
NUWIQ	
WILATE	
XYNTHA	
HEPATITIS C AGENTS	
EPCLUSA	HARVONI
MAVYRET	SOVALDI
VOSEVI	
ZEPATIER	
HIV / AIDS	
ABACAVIR/LAMIVUDINE	
DESCOVY	
EVOTAZ	
GENVOYA	
LAMIVUDINE SOLUTION	
NORVIR TABLET	
ODEFSEY	
PREZCOBIX	
HYPERPARATHYROID AGENTS	
	RAYALDEE
HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS	

PREFERRED AGENTS	NON-PREFERRED AGENTS
BYDUREON PENS	BYDUREON BCISE
JANUMET	GLYXAMBI
JANUVIA	JANUMET XR
VICTOZA	QTERN
	XULTOPHY
HYPOGLYCEMICS, INSULIN AND RELATED AGENTS	
HUMULIN 70/30 VIAL OTC	HUMALOG 200 U/ML PEN
HUMULIN VIAL OTC	TRESIBA
HYPOGLYCEMICS, SGLT2	
	FARXIGA
	INVOKAMET
	INVOKAMET XR
	INVOKANA
	JARDIANCE
	SYNJARDY
	SYNJARDY XR
	XIGDUO XR
LAXATIVES & CATHARTICS	
PREPOPIK	GAVILYTE-H AND BISACODYL
LIPOTROPICS, OTHER	
	FENOFIBRATE (Generic for ANTARA) (Authorized Generic & Non-Authorized Generic)
	FENOFIBRATE CAPSULE (Generic for LIPOFEN)
	FENOFIBRATE CAPSULE (Generic for LOFIBRA)
	REPATHA
	TRIGLIDE
MULTIPLE SCLEROSIS AGENTS	
AUBAGIO	COPAXONE 40MG/ML
BETASERON	PLEGRIDY
GILENYA	
REBIF	
TECFIDERA	
OPIATE DEPENDENCE TREATMENTS	
SUBOXONE	BUNAVAIL
VIVITROL	ZUBSOLV
PAH AGENTS, ORAL AND INHALED	
LETAIRIS	OPSUMIT
TRACLEER TABLET	
PANCREATIC ENZYMES	

PREFERRED AGENTS	NON-PREFERRED AGENTS
CREON	PERTZYE
ZENPEP	
PHOSPHATE BINDERS	
	CALCIUM ACETATE TABLET
	FOSRENOL
	PHOSLYRA
PLATELET AGGREGATION INHIBITORS	
BRILINTA	
PRENATAL VITAMINS	
CONCEPT DHA, OB	
PRENATE AM, CHEWABLE TABLET, DHA, ELITE, ENHANCE, MINI, PIXI, RESTORE	
PRIMACARE	
PROVIDA DHA, OB	
TRICARE	
SMOKING CESSATION	
CHANTIX	
ULCERATIVE COLITIS AGENTS	
LIALDA	MESALAMINE RECTAL
PENTASA	MESALAMINE RECTAL KIT

This page intentionally left blank

**Georgia Department of Community Health (GDCH)
Opportunities for Pharmaceutical Manufacturer Input on Clinical
Recommendations and Clinical Management Strategies by the
Drug Utilization Review Board**

Clinical Information and Clinical Management Strategies relevant to the GDCH Medicaid Fee-For-Service program will be presented to the Drug Utilization Review Board (DURB) at each meeting through OptumRx by its vendor NorthStar HealthCare Consulting (NHC). Manufacturer input on new and existing drugs is welcomed and appreciated using these opportunities. **Please note that new drug entities are generally not reviewed by the DURB until the drug has been on the market for at least 6 months.**

Ongoing Opportunity:

DUR Board Meeting Process: Drugs, therapeutic classes and/or supplemental rebate classes under review will be posted to the DCH website at <http://dch.georgia.gov/durb-meeting-information> approximately 30 days prior to the Manufacturers' Forum. Input specific to the drugs under review from manufacturers are made directly to NHC via GAMedicaid@nhc-llc.com and reported as appropriate by NHC at subsequent DURB meetings. NHC will pass relevant manufacturer-submitted electronic materials to the DURB members via a secure FTP site.

Upon review of information, and based on its expertise and discussions, the DURB makes recommendations to GDCH.

Opportunity to Appeal to GDCH:

GDCH Review Process: DURB recommendations are reviewed by GDCH for final decisions. Manufacturers may request an appeal meeting directly with GDCH after conclusion of each quarterly DURB meeting and **this appeal meeting must be conducted within 10 business days following the DURB meeting.** **Contact: Shirmary Hodges at (404) 656-4044 or shodges@dch.ga.gov**

Presentation Opportunity:

Manufacturers' Forum: A forum prior to each relevant DURB meeting whereby manufacturers may present:

- 1) Clinical information relevant to a new drug on the market or a drug that is part of a therapeutic or supplemental rebate class under review by the DURB at the next meeting.
- 2) Clinical information relevant to ongoing NHC/OptumRx clinical management strategies (e.g. review of drug benefit plan designs, new drugs coming to market, new indications, etc.) as deemed necessary by NHC/OptumRx.

Please see the Manufacturers' Forum Announcement at <http://dch.georgia.gov/durb-meeting-information>.

**Questions not addressed in this document may be sent to NorthStar
HealthCare Consulting by e-mail: GAMedicaid@nhc-llc.com**

This page intentionally left blank

2018

Upcoming Meetings

Drug Utilization Review Board Meeting

2 Peachtree Street, N.W.

5th Floor Board Room

Atlanta, Georgia 30303

Tuesday, November 6, 2018:

9:30am – 1:30pm

This page intentionally left blank

Drug Utilization Review Board

Board Member	Credentials	Specialty/Area of Expertise	Company Name
Burton L. Lesnick, Chair	M.D., FAAP	Pediatrics/Pediatric Pulmonology	Children's Healthcare of Atlanta
M. Celeste Fowler, Vice-Chair	Pharm.D., HCMBA	340B Pharmacy	Piedmont Henry Hospital
Mia Avery	Pharm.D.	Oncology Pharmacy	Emory University Hospital Winship Cancer Institute
Douglas C. Collins	M.D.	Hematology/Oncology	Metro Hematology-Oncology, PC
Gurinder J.S. Doad	M.D., Ph.D.	Family Practice	Southwest Georgia Family Medicine and Mercer University School of Medicine
Rod M. Duraski	M.D., FACP, MBA	Internal Medicine	West Georgia Health
Deborah W. Fincher	R.Ph., M.S.	HIV/AIDS Pharmacy	Pride Medical Pharmacy
Glenda Gordon	M.D.	Psychiatry, Academia - Professor	Morehouse School of Medicine
Robyn Lorys	Pharm.D.	Academia - Professor	Mercer University College of Pharmacy
J. Russell May	Pharm.D.	Academia - Professor	University of Georgia College of Pharmacy
Drew A. Miller	R.Ph.	Retail Pharmacy	Wynn's Pharmacy
Brent L. Rollins	R.Ph., Ph.D.	Academia - Professor	Philadelphia College of Osteopathic Medicine School of Pharmacy
Danny A. Toth	R.Ph.	Pharmacy Benefit Plans	Timber Ridge Consultants, LLC